Moderna Inc.: Diferență între versiuni
Admin (discuție | contribuții) (csv2wiki) |
Admin (discuție | contribuții) Fără descriere a modificării |
||
(Nu s-a afișat o versiune intermediară efectuată de același utilizator) | |||
Linia 1: | Linia 1: | ||
Pagina dedicata companiei Moderna Inc. listata cu simbolul US.MRNA | Pagina dedicata companiei Moderna Inc. listata cu simbolul US.MRNA | ||
Linia 5: | Linia 4: | ||
Moderna, Inc. (https://www.modernatx.com/) is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics. | Moderna, Inc. (https://www.modernatx.com/) is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics. | ||
==Grafic actiuni companie== | |||
<iframe key="tradeville" path="graficSimbol/US.MRNA" /> | |||
==Ultimele stiri despre Moderna Inc. (US.MRNA)== | ==Ultimele stiri despre Moderna Inc. (US.MRNA)== | ||
Linia 13: | Linia 14: | ||
addfirstcategorydate=false | addfirstcategorydate=false | ||
</dynamicpagelist> | </dynamicpagelist> | ||
[[Categorie:US.MRNA]][[Categorie:Stiri despre companii]] | [[Categorie:US.MRNA]][[Categorie:Stiri despre companii]] |
Versiunea curentă din 18 septembrie 2024 20:13
Pagina dedicata companiei Moderna Inc. listata cu simbolul US.MRNA
Descriere companie[edit | ]
Moderna, Inc. (https://www.modernatx.com/) is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Grafic actiuni companie[edit | ]
Ultimele stiri despre Moderna Inc. (US.MRNA)[edit | ]
- Fondurile mutuale ar putea ajunge la 1 mil. investitori - 13 septembrie 2024
- Somajul in Romania, in usoara crestere - 02 august 2024
- Fidelis, la finalul celei de-a treia editii din 2024 - 03 iulie 2024
- Romania, cea mai ridicata rata a inflatiei din UE - 23 februarie 2024
- Vanzari in crestere in comertul cu amanuntul - 07 septembrie 2023
- Piata asigurarilor, in crestere - 05 mai 2023
- 📉 Indicele DJIA: a 2-a saptamana consecutiva pe minus
- Indicele DJIA: a 4-a zi consecutiva pe minus
- Romanii - mai atenti cu becurile aprinse - 15 decembrie 2022
- Vaccine maker stocks rise as China battles worst Covid outbreak since 2020 - 15 martie 2022